Imperial Valley News Center
Secretary of State Tillerson Travel to Saudi Arabia, Qatar, Pakistan, India, and Switzerland
- Details
- Written by State Department
Washington, DC - U.S. Secretary of State Rex Tillerson will travel to Riyadh, Doha, Islamabad, New Delhi, and Geneva October 20-27.
Victory Media Settles FTC Charges Concerning Its Promotion of Post-Secondary Schools to Military Consumers
- Details
- Written by IVN
Washington, DC - The Federal Trade Commission and Victory Media, Inc. have reached a proposed administrative consent agreement resolving allegations that Victory Media violated Section 5 of the FTC Act in connection with its promotion of post-secondary schools to military consumers.
Alert: Researchers spot bug in Wi-Fi network encryption
- Details
- Written by Phoebe Rouge
Washington, DC - You’ve read recent news stories about a vulnerability discovered in the WPA2 encryption standard. (Some reports refer to it as KRACK – Key Reinstallation Attack.) Should this be of concern to your business? Yes. Does it warrant further action at your company? Absolutely.
Governor Brown Issues Executive Order to Help Cut Red Tape, Expedite Recovery Efforts in Communities Impacted by Wildfires
- Details
- Written by IVN
Sacramento, California - Governor Edmund G. Brown Jr. today issued an executive order to cut red tape and help streamline recovery efforts in communities impacted by the devastating wildfires that have burned across California over the past ten days.
Les Chateaux De France, Inc. Recalls Bacon-Wrapped Scallops
- Details
- Written by FDA
Washington, DC - Les Chateaux De France, Inc., an Inwood, N.Y. establishment, is recalling approximately 4,225 pounds of bacon-wrapped scallops due to misbranding and an undeclared allergen, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced today. The products contain milk, a known allergen, which was not declared on the product label.
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
- Details
- Written by IVN
Washington, DC - The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).
Page 1721 of 3785